Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Wilson H Miller

Showing results (111-120 of 168) with videos related to

Pageof 17
Sort By:
Cell Death & Disease|May 6, 2026
mTOR inhibition enhances the antitumor efficacy of pan-RAF-MEK blockade by inhibiting the ATF4-MTHFD2 pathwayFeiyang Cai, Fan Huang, Christophe Goncalves, et al.
Breast Cancer Research : BCR|May 4, 2017
A phase-I study of lapatinib in combination with foretinib, a c-MET, AXL and vascular endothelial growth factor receptor inhibitor, in human epidermal growth factor receptor 2 (HER-2)-positive metastatic breast cancerStephen K Chia, Susan L Ellard, Mihaela Mates, et al.
Cancer Immunology Research|December 29, 2025
The CCL17-CCR4 axis is critical for mutant STAT6-mediated microenvironmental remodelling and therapeutic resistance in Relapsed/Refractory Diffuse Large B-cell LymphomaMadelyn J Abraham, Cynthia Guilbert, Natascha Gagnon, et al.
Frontiers in Medicine|March 21, 2022
Population-Based Study Detailing Cutaneous Melanoma Incidence and Mortality Trends in CanadaSantina Conte, Feras M Ghazawi, Michelle Le, et al.
Cancers|August 12, 2023
Assessing Skin Cancer Risk Factors, Sun Safety Behaviors and Melanoma Concern in Atlantic Canada: A Comprehensive Survey StudyFrançois Lagacé, Bibi Nuzha Noorah, Santina Conte, et al.
Journal for Immunotherapy of Cancer|November 22, 2017
Peripheral and local predictive immune signatures identified in a phase II trial of ipilimumab with carboplatin/paclitaxel in unresectable stage III or stage IV melanomaRahima Jamal, Réjean Lapointe, Eftihia Cocolakis, et al.
Nature Medicine|June 8, 2019
Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanomaAntoni Ribas, Donald Lawrence, Victoria Atkinson, et al.
Dermatology (Basel, Switzerland)|June 9, 2022
Analysis of Geographic and Environmental Factors and Their Association with Cutaneous Melanoma Incidence in CanadaMelissa Berman-Rosa, James Logan, Feras M Ghazawi, et al.
Journal for Immunotherapy of Cancer|May 16, 2014
Recombinant interleukin-21 plus sorafenib for metastatic renal cell carcinoma: a phase 1/2 studyShailender Bhatia, Brendan Curti, Marc S Ernstoff, et al.
European Journal of Cancer (Oxford, England : 1990)|November 21, 2021
KEYNOTE-022: Pembrolizumab with trametinib in patients with BRAF wild-type melanoma or advanced solid tumours irrespective of BRAF mutationMichele Maio, Matteo S Carlino, Anthony M Joshua, et al.
Pageof 17

Showing results (111-120 of 168) with videos related to

Sort By:
Pageof 17
Cell Death & Disease|May 6, 2026
mTOR inhibition enhances the antitumor efficacy of pan-RAF-MEK blockade by inhibiting the ATF4-MTHFD2 pathwayFeiyang Cai, Fan Huang, Christophe Goncalves, et al.
Breast Cancer Research : BCR|May 4, 2017
A phase-I study of lapatinib in combination with foretinib, a c-MET, AXL and vascular endothelial growth factor receptor inhibitor, in human epidermal growth factor receptor 2 (HER-2)-positive metastatic breast cancerStephen K Chia, Susan L Ellard, Mihaela Mates, et al.
Cancer Immunology Research|December 29, 2025
The CCL17-CCR4 axis is critical for mutant STAT6-mediated microenvironmental remodelling and therapeutic resistance in Relapsed/Refractory Diffuse Large B-cell LymphomaMadelyn J Abraham, Cynthia Guilbert, Natascha Gagnon, et al.
Frontiers in Medicine|March 21, 2022
Population-Based Study Detailing Cutaneous Melanoma Incidence and Mortality Trends in CanadaSantina Conte, Feras M Ghazawi, Michelle Le, et al.
Cancers|August 12, 2023
Assessing Skin Cancer Risk Factors, Sun Safety Behaviors and Melanoma Concern in Atlantic Canada: A Comprehensive Survey StudyFrançois Lagacé, Bibi Nuzha Noorah, Santina Conte, et al.
Journal for Immunotherapy of Cancer|November 22, 2017
Peripheral and local predictive immune signatures identified in a phase II trial of ipilimumab with carboplatin/paclitaxel in unresectable stage III or stage IV melanomaRahima Jamal, Réjean Lapointe, Eftihia Cocolakis, et al.
Nature Medicine|June 8, 2019
Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanomaAntoni Ribas, Donald Lawrence, Victoria Atkinson, et al.
Dermatology (Basel, Switzerland)|June 9, 2022
Analysis of Geographic and Environmental Factors and Their Association with Cutaneous Melanoma Incidence in CanadaMelissa Berman-Rosa, James Logan, Feras M Ghazawi, et al.
Journal for Immunotherapy of Cancer|May 16, 2014
Recombinant interleukin-21 plus sorafenib for metastatic renal cell carcinoma: a phase 1/2 studyShailender Bhatia, Brendan Curti, Marc S Ernstoff, et al.
European Journal of Cancer (Oxford, England : 1990)|November 21, 2021
KEYNOTE-022: Pembrolizumab with trametinib in patients with BRAF wild-type melanoma or advanced solid tumours irrespective of BRAF mutationMichele Maio, Matteo S Carlino, Anthony M Joshua, et al.
Pageof 17